Alpha Cognition EBITDA 2020-2024 | ACOG
Alpha Cognition ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Alpha Cognition Annual EBITDA
(Millions of US $) |
| 2023 |
$-10 |
| 2022 |
$-13 |
| 2021 |
$-12 |
| 2020 |
$-6 |
| 2019 |
$-6 |
Alpha Cognition Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$-2 |
| 2024-03-31 |
$-4 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-3 |
| 2023-06-30 |
$-3 |
| 2023-03-31 |
$-2 |
| 2022-12-31 |
$-3 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-4 |
| 2022-03-31 |
$-3 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-3 |
| 2021-06-30 |
$-2 |
| 2021-03-31 |
$-2 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-1 |
| 2020-06-30 |
$-2 |
| 2020-03-31 |
$-1 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
|
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|
